Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Scarpi

Showing results (101-110 of 215) with videos related to

Pageof 22
Sort By:
Scientific Reports|March 2, 2022
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumabMichela Palleschi, Andrea Prochowski Iamurri, Emanuela Scarpi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2015
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Frontiers in Pharmacology|October 30, 2016
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with AbirateroneCristian Lolli, Orazio Caffo, Emanuela Scarpi, et al.
Plos One|March 20, 2014
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)Andrea Casadei Gardini, Laura Capelli, Paola Ulivi, et al.
International Journal of Molecular Sciences|May 25, 2013
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective studyLaura Mercatali, Marianna Ricci, Emanuela Scarpi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Therapeutic Advances in Medical Oncology|October 16, 2020
Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trialAndrea Casadei Gardini, Emanuela Scarpi, Martina Valgiusti, et al.
Journal of Translational Medicine|August 12, 2015
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trialPaola Ulivi, Emanuela Scarpi, Alessandro Passardi, et al.
Radiation Oncology (London, England)|June 26, 2019
Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-upElisabetta Parisi, Giovenzio Genestreti, Anna Sarnelli, et al.
Oncotarget|May 19, 2016
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancerSamanta Salvi, Valentina Casadio, Vincenza Conteduca, et al.
Pageof 22

Showing results (101-110 of 215) with videos related to

Sort By:
Pageof 22
Scientific Reports|March 2, 2022
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumabMichela Palleschi, Andrea Prochowski Iamurri, Emanuela Scarpi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2015
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Frontiers in Pharmacology|October 30, 2016
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with AbirateroneCristian Lolli, Orazio Caffo, Emanuela Scarpi, et al.
Plos One|March 20, 2014
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)Andrea Casadei Gardini, Laura Capelli, Paola Ulivi, et al.
International Journal of Molecular Sciences|May 25, 2013
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective studyLaura Mercatali, Marianna Ricci, Emanuela Scarpi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Therapeutic Advances in Medical Oncology|October 16, 2020
Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trialAndrea Casadei Gardini, Emanuela Scarpi, Martina Valgiusti, et al.
Journal of Translational Medicine|August 12, 2015
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trialPaola Ulivi, Emanuela Scarpi, Alessandro Passardi, et al.
Radiation Oncology (London, England)|June 26, 2019
Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-upElisabetta Parisi, Giovenzio Genestreti, Anna Sarnelli, et al.
Oncotarget|May 19, 2016
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancerSamanta Salvi, Valentina Casadio, Vincenza Conteduca, et al.
Pageof 22